Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
Imprimis Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 26, 2022
Imprimis Pharmaceuticals reported fiscal year 2021 executive compensation information on April 26, 2022.
In 2021, three executives at Imprimis Pharmaceuticals received on average a compensation package of $4.5M, a 231% increase compared to previous year.
Average pay of disclosed executives at Imprimis Pharmaceuticals
Mark L. Baum, Chief Executive Officer, received $7.3M in total, which increased by 195% compared to 2020. 85% of Baum's compensation, or $6.3M, was in stock awards. Baum also received $493K in non-equity incentive plan, $565K in salary, as well as $13K in other compensation.
Andrew R. Boll, Chief Financial Officer, received a compensation package of $3.4M, which increased by 230% compared to previous year. 79% of the compensation package, or $2.6M, was in stock awards.
John P. Saharek, President, ImprimisRx, earned $2.7M in 2021, a 402% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 26, 2022.